Logo Logo

Publications by Ormanns, S.

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 8.

Journal article

Sams, L.; Kruger, S.; Heinemann, V.; Bararia, D.; Haebe, S.; Alig, S.; Haas, M.; Zhang, D.; Westphalen, C. B.; Ormanns, S.; Metzger, P.; Werner, J.; Weigert, O.; von Bergwelt-Baildon, M.; Rataj, F.; Kobold, S.; Boeck, S. (2021): Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel. In: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [PDF, 1MB]

Krüger, S.; Heinemann, V.; Ross, C.; Diehl, F.; Nagel, D.; Ormanns, S.; Liebmann, S.; Prinz-Bravin, I.; Westphalen, C. B.; Haas, M.; Jung, A.; Kirchner, T.; Bergwelt-Baildon, M. von; Böck, S.; Holdenrieder, S. (2018): Repeated (mut)KRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. In: Annals of Oncology, Vol. 29, No. 12: pp. 2348-2355

Ormanns, S. (2018): Personalisierte Krebsmedizin. Biomarker zur molekularen Therapiestratifizierung im Pankreaskarzinom. In: Pathologe, Vol. 39, No. Suppl. 2: pp. 221-224

Böck, S.; Mehraein, Y.; Ormanns, S.; Kruger, S.; Westphalen, C. Benedikt; Haas, M.; Jung, A.; Kirchner, T.; Heinemann, V. (2017): Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical course. In: Annals of Oncology, Vol. 28, No. 2: pp. 438-439

Kruger, S.; Ormanns, S.; Rösgen, V.; Legenstein, M.-L.; Haas, M.; Westphalen, C. B.; Düwell, P.; Schnurr, M.; Heinemann, V.; Kirchner, T.; Böck, S. (2017): IDO1 expression as biomarker in erlotinib-treated patients with advanced pancreatic cancer: translational results from the AIO-PK0104 phase III trial. In: Oncology Research and Treatment, Vol. 40: p. 235

Burger, P. J.; Kruger, S.; Jühling, A.; Kapp, M.; Berger, A. W.; Ormanns, S.; Ettrich, T. J.; Waidmann, O.; Steiner, B.; Kunzmann, V.; Abendroth, A.; Sinn, M.; Werner, J.; Kirchner, T.; Heinemann, V.; Böck, S. (2017): Isolated pulmonary metastases in pancreatic cancer: preliminary results from the retrospective multi-center AIO-YMO-PAK-0515 study. In: Oncology Research and Treatment, Vol. 40: pp. 236-237

Boeck, S.; Ormanns, S.; Haas, M.; Bachmann, S.; Laubender, Rüdiger P.; Siveke, J. T.; Jung, A.; Kirchner, T.; Heinemann, V. (2014): Translational research in pancreatic cancer: KRAS and beyond. In: Pancreas, Vol. 43, No. 1: pp. 150-152

Boeck, S.; Jung, A.; Laubender, Rüdiger P.; Neumann, J.; Egg, R.; Goritschan, C.; Ormanns, S.; Haas, M.; Modest, D. P.; Kirchner, T.; Heinemann, V. (2013): KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer. In: Journal of Gastroenterology, Vol. 48, No. 4: pp. 544-548

This list was generated on Tue Oct 26 00:21:45 2021 CEST.